Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Eren Yıldızhan, Eda Uzun & Nesrin Buket Tomruk. (2022) Effect of long acting injectable antipsychotics on course and hospitalizations in bipolar disorder – a naturalistic mirror image study. Nordic Journal of Psychiatry 76:1, pages 37-43.
Read now
Read now
Ludovic Samalin, Aurore Nourry, Thomas Charpeaud & Pierre-Michel Llorca. (2014) What is the evidence for the use of second-generation antipsychotic long-acting injectables as maintenance treatment in bipolar disorder?. Nordic Journal of Psychiatry 68:4, pages 227-235.
Read now
Read now
Heinz Grunze, Eduard Vieta, Guy M. Goodwin, Charles Bowden, Rasmus W. Licht, Hans-Jürgen Möller & Siegfried Kasper. (2013) The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2012 on the long-term treatment of bipolar disorder. The World Journal of Biological Psychiatry 14:3, pages 154-219.
Read now
Read now
Eduard Vieta & Francesc Colom. (2011) Therapeutic options in treatment-resistant depression. Annals of Medicine 43:7, pages 512-530.
Read now
Read now
L Samalin, T Charpeaud, O Lorabi & PM Llorca. (2010) Patient perspectives on use of long-acting antipsychotics in bipolar disorder: focus on risperidone injection. Patient Preference and Adherence 4, pages 325-334.
Read now
Read now
Wissam El-Hage & Simon A Surguladze. (2010) Emerging treatments in the management of bipolar disorder – focus on risperidone long acting injection. Neuropsychiatric Disease and Treatment 6, pages 455-464.
Read now
Read now
William V Bobo & Richard C Shelton. (2010) Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder. Expert Review of Neurotherapeutics 10:11, pages 1637-1658.
Read now
Read now
Andrea Fagiolini, Francesco Casamassima, Wilmer Mostacciuolo, Rocco Forgione, Arianna Goracci & Benjamin I Goldstein. (2010) Risperidone long-acting injection as monotherapy and adjunctive therapy in the maintenance treatment of bipolar I disorder. Expert Opinion on Pharmacotherapy 11:10, pages 1727-1740.
Read now
Read now
Articles from other publishers (29)
Francesco Bartoli, Bianca Bachi, Angela Calabrese, Riccardo Matteo Cioni, Pierluca Guzzi, Christian Nasti, Dario Palpella, Filippo Fabio Barbieri, Serena Limonta, Cristina Crocamo & Giuseppe Carrà. (2022) Effect of long-acting injectable antipsychotics on emergency department visits and hospital admissions in people with bipolar disorder: A retrospective mirror-image analysis from the Northern Milan Area Cohort (NOMIAC) study. Journal of Affective Disorders 318, pages 88-93.
Crossref
Crossref
Ali Metehan Caliskan, Munir Karaaslan, Ikbal Inanli, Sila Caliskan, Mehmet Arslan, Ismet Esra Cicek & Ibrahim Eren. (2020) The effects of adding long-acting injectable antipsychotic drugs to clozapine on relapse and hospitalization in patients with treatment-resistant schizophrenia: a mirror-image retrospective study. International Clinical Psychopharmacology 36:1, pages 30-33.
Crossref
Crossref
Ali Metehan Caliskan, Saliha Calisir, Sila Caliskan, Mehmet Arslan, Ikbal Inanli & Ibrahim Eren. (2020) Impact of initiating long-acting injectable paliperidone palmitate on relapse and hospitalization in patients with bipolar I disorder: A mirror image retrospective study. Asian Journal of Psychiatry 54, pages 102457.
Crossref
Crossref
Estela Salagre, Eduard Vieta & Iria Grande. 2020. Personalized Psychiatry. Personalized Psychiatry
423
436
.
Kamyar Keramatian, Trisha Chakrabarty & Lakshmi N. Yatham. (2019) Long-Acting Injectable Second-Generation/Atypical Antipsychotics for the Management of Bipolar Disorder: A Systematic Review. CNS Drugs 33:5, pages 431-456.
Crossref
Crossref
Isabella Pacchiarotti, Jari Tiihonen, Georgios D. Kotzalidis, Norma Verdolini, Andrea Murru, José Manuel Goikolea, Marc Valentí, Alberto Aedo & Eduard Vieta. (2019) Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review. European Neuropsychopharmacology 29:4, pages 457-470.
Crossref
Crossref
Philip Boyce, Lauren Irwin, Grace Morris, Amber Hamilton, Roger Mulder, Gin S Malhi & Richard J Porter. (2018) Long-acting injectable antipsychotics as maintenance treatments for bipolar disorder-A critical review of the evidence. Bipolar Disorders 20, pages 25-36.
Crossref
Crossref
Ulku Akyol Ardic, Mustafa Küçükköse, Sevim Berrin Inci & Eyüp Sabri Ercan. (2018) Efficacy and Safety Profile of Risperidone Long-acting Injection in Adolescents in a Real-life Setting. Clinical Psychopharmacology and Neuroscience 16:1, pages 57-61.
Crossref
Crossref
Sevcan Karakoç Demirkaya, Hatice Aksu & Börte Gürbüz Özgür. (2017) A Retrospective Study of Long Acting Risperidone Use to Support Treatment Adherence in Youth with Conduct Disorder. Clinical Psychopharmacology and Neuroscience 15:4, pages 328-336.
Crossref
Crossref
Joseph R. Calabrese, Andrei Pikalov, Caroline Streicher, Josephine Cucchiaro, Yongcai Mao & Antony Loebel. (2017) Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder. European Neuropsychopharmacology 27:9, pages 865-876.
Crossref
Crossref
Ming H. Hsieh, Po-Ya Chuang, Chi-Shin Wu, Ching-Jui Chang, Pei-Fang Chung & Chao-Hsiun Tang. (2017) Bipolar patients treated with long-acting injectable risperidone in Taiwan: A 1-year mirror-image study using a national claims database. Journal of Affective Disorders 218, pages 327-334.
Crossref
Crossref
Hsue-Wei Chan, Chin-Yu Huang, Wen-Jui Feng & Yung-Chieh Yen. (2016) Clinical outcomes of long-acting injectable risperidone in patients with bipolar I disorder: A 1-year retrospective cohort study. Journal of Affective Disorders 205, pages 360-364.
Crossref
Crossref
Jennifer B. Levin, Anna Krivenko, Molly Howland, Rebecca Schlachet & Martha Sajatovic. (2016) Medication Adherence in Patients with Bipolar Disorder: A Comprehensive Review. CNS Drugs 30:9, pages 819-835.
Crossref
Crossref
Chi-Shin Wu, Ming H. Hsieh, Chao-Hsiun Tang & Ching-Jui Chang. (2016) Comparative effectiveness of long-acting injectable risperidone vs. long-acting injectable first-generation antipsychotics in bipolar disorder. Journal of Affective Disorders 197, pages 189-195.
Crossref
Crossref
Majella Su-Xian Chew, Rohan Dhillon, Prashant Tibrewal & Birinder Narang. (2013) Olanzapine long-acting injection: When and for how long is oral supplementation required?. Australian & New Zealand Journal of Psychiatry 47:12, pages 1214-1215.
Crossref
Crossref
Boghos I Yerevanian & Young Mee Choi. (2013) Impact of psychotropic drugs on suicide and suicidal behaviors. Bipolar Disorders 15:5, pages 594-621.
Crossref
Crossref
Eduard Vieta & Marc Valentí. (2013) Pharmacological Management of Bipolar Depression: Acute Treatment, Maintenance, and Prophylaxis. CNS Drugs 27:7, pages 515-529.
Crossref
Crossref
Lakshmi N Yatham, Sidney H Kennedy, Sagar V Parikh, Ayal Schaffer, Serge Beaulieu, Martin Alda, Claire O’Donovan, Glenda MacQueen, Roger S McIntyre, Verinder Sharma, Arun Ravindran, L Trevor Young, Roumen Milev, David J Bond, Benicio N Frey, Benjamin I Goldstein, Beny Lafer, Boris Birmaher, Kyooseob Ha, Willem A Nolen & Michael Berk. (2012) Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disorders 15:1, pages 1-44.
Crossref
Crossref
Ralph J. Koek, Boghos I. Yerevanian & Jim Mintz. (2012) Subtypes of antipsychotics and suicidal behavior in bipolar disorder. Journal of Affective Disorders 143:1-3, pages 27-33.
Crossref
Crossref
Eduard Vieta, Stuart Montgomery, Ahmad Hatim Sulaiman, Rodrigo Cordoba, Benedicte Huberlant, Lupe Martinez & Andreas Schreiner. (2012) A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder. European Neuropsychopharmacology 22:11, pages 825-835.
Crossref
Crossref
Alexandre Duarte Gigante, Beny Lafer & Lakshmi N. Yatham. (2012) Long-Acting Injectable Antipsychotics for the Maintenance Treatment of Bipolar Disorder. CNS Drugs 26:5, pages 403-420.
Crossref
Crossref
Kate E. A. Saunders & G. M. Goodwin. 2013. Behavioral Neurobiology of Depression and Its Treatment. Behavioral Neurobiology of Depression and Its Treatment
291
307
.
Wayne Macfadden, Caleb M Adler, Ibrahim Turkoz, John T Haskins, Norris Turner & Larry Alphs. (2011) Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms. BMC Psychiatry 11:1.
Crossref
Crossref
P.-M. Llorca. (2011) Antipsychotiques de seconde génération dans la dépression bipolaire : une nouvelle option thérapeutique ?. L'Encéphale 37, pages S209-S213.
Crossref
Crossref
A. Murru, I. Pacchiarotti, A.M.A. Nivoli, I. Grande, F. Colom & E. Vieta. (2011) What we know and what we don't know about the treatment of schizoaffective disorder. European Neuropsychopharmacology 21:9, pages 680-690.
Crossref
Crossref
L. Ivo Caers & Joris Berwaerts. 2011. Bipolar Psychopharmacotherapy. Bipolar Psychopharmacotherapy
153
192
.
Roger S. McIntyre, Miriam Cohen, Jun Zhao, Larry Alphs, Thomas A. Macek & John Panagides. (2010) Asenapine for long-term treatment of bipolar disorder: A double-blind 40-week extension study. Journal of Affective Disorders 126:3, pages 358-365.
Crossref
Crossref
S. Gentile. (2009) Contributing factors to weight gain during long-term treatment with second-generation antipsychotics. A systematic appraisal and clinical implications. Obesity Reviews 10:5, pages 527-542.
Crossref
Crossref
GM Goodwin. (2009) Evidence-based guidelines for treating bipolar disorder: revised second edition—recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 23:4, pages 346-388.
Crossref
Crossref